Vol.5 No.3 2012

78/94

Research paper : Development of basic tools for glycoscience and their application to cancer diagnosis (H. Narimatsu)−213−Synthesiology - English edition Vol.5 No.3 (2012) AuthorHisashi NarimatsuGraduated the Keio University School of Medicine and received M.D. in 1974. Completed the Keio University Graduate School of Medicine and received Ph.D. in 1979. Became an associate professor at the Keio University School of Medicine and a professor at the Institute of Life Science, Soka University in 1991. Joined the Institute of Molecular and Cell Biology, AIST as a principal research scientist in 2001 and became the director of RCMG since 2006. Currently, also serves as a professor of the Graduate School of Comprehensive Human Sciences, Tsukuba University, a visiting professor of the School of Medicine, Keio University, and the advisory professor for the Shanghai Jiao Tong University. Specialties are glycobiology, biochemistry, immunology, microbiology, and tumor biology. Received the Nikkei BP Technological Award in 2007, Chemistry-Bio Tsukuba Award in 2010, Tsukuba Award in 2011. Affiliations: councilor, The Japanese Society of Carbohydrate Research General; council member, Japan Consortium for Glycobiology and Glycotechnology; council member, Human Proteome Organization (HUPO); council member, Japan Human Proteome Organization (JHUPO); councilor, the Japanese Biochemical Society; councilor, Japan Society for Molecular Marker Research; cooperation member, Science Council of Japan; member of Japan Cancer Association. Narimatsu and K. Kimata: Chondroitin sulfate synthase-3: molecular cloning and characterization, J. Biol. Chem., 278(41), 39711-39725 (2003).[29]Y. Zhang, H. Iwasaki, H. Wang, T. Kudo, T.B. Kalka, T. Hennet, T. Kubota, L. Cheng, N. Inaba, M. Gotoh, A. Togayachi, J. Guo, H. Hisatomi, K. Nakajima, S. Nishihara, M. Nakamura, J.D. Marth and H. Narimatsu: Cloning and characterization of a new human UDP-N-acetyl--D-galactosamine:polypeptide N-acetylgalactosaminyltransferase, designated pp-GalNAc-T13, that is specifically expressed in neurons and synthesizes GalNAc -serine/threonine antigen, J. Biol. Chem., 278(1), 573-584 (2003).[30]K. Amano, Y. Chiba, Y. Kasahara, Y. Kato, M.K. Kaneko, A. Kuno, H. Ito, K. Kobayashi, J. Hirabayashi, Y. Jigami and H. Narimatsu: Engineering of mucin-type human glycoproteins in yeast cells, Proc. Natl. Acad. Sci., 105(9), 3232-3237 (2008).[31]H. Ito, A. Kuno, H. Sawaki, M. Sogabe, H. Ozaki, Y. Tanaka, M. Mizokami, J. Shoda, T. Angata, T. Sato, J. Hirabayashi, Y. Ikehara and H. Narimatsu: Strategy for glycoproteomics: identification of glyco-alteration using multiple glycan profiling tools, J. Proteome Res., 8(3), 1358-1367 (2009).[32]M.K. Kaneko, Y. Kato, A. Kameyama, H. Ito, A. Kuno, J. Hirabayashi, T. Kubota, K. Amano, Y. Chiba, Y. Hasegawa, I. Sasagawa, K. Mishima and H. Narimatsu: Functional glycosylation of human podoplanin: glycan structure of platelet aggregation-inducing factor, FEBS Lett., 581(2), 331-336 (2007).[33]Y. Kato, M.K. Kaneko, A. Kuno, N. Uchiyama, K. Amano, Y. Chiba, Y. Hasegawa, J. Hirabayashi, H. Narimatsu, K. Mishima and M. Osawa: Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain, Biochem. Biophys. Res. Commun., 349(4), 1301-1307 (2006).[34]H. Ito, A. Kameyama, T. Sato, K. Kiyohara, Y. Nakahara and H. Narimatsu: Molecular-weight-tagged glycopeptide library: efficient construction and applications, Angew. Chem. Int. Ed., 44(29), 4547-4549 (2005).[35]H. Ito, A. Kameyama, T. Sato, M. Sukegawa, H.K. Ishida and H. Narimatsu: Strategy for the fine characterization of glycosyltransferase specificity using isotopomer assembly, Nat. Methods, 4(7), 577-582 (2007).[36]H. Kaji, H. Saito, Y. Yamauchi, T. Shinkawa, M. Taoka, J. Hirabayashi, K. Kasai, N. Takahashi and T. Isobe: Lectin affinity capture, isotope-coded tagging and mass spectrometry to identify N-linked glycoproteins, Nat. Biotechnol., 21(6), 667-672 (2003).[37]H. Kaji, Y. Yamauchi, N. Takahashi and T. Isobe: Mass spectrometric identification of N-linked glycopeptides using lectin-mediated affinity capture and glycosylation site-specific stable isotope tagging, Nat. Protoc., 1(6), 3019-3027 (2006).[38]A. Kuno, Y. Kato, A. Matsuda, M.K. Kaneko, H. Ito, K. Amano, Y. Chiba, H. Narimatsu and J. Hirabayashi: Focused differential glycan analysis with the platform antibody-assisted lectin profiling for glycan-related biomarker verification, Mol. Cell Proteomics, 8(1), 99-108 (2009).[39]A. Kuno, A. Matsuda, Y. Ikehara, H. Narimatsu and J. Hirabayashi: Differential glycan profiling by lectin microarray targeting tissue specimens, Methods Enzymol., 478, 165-179 (2010).[40]H. Narimatsu, H. Sawaki, A. Kuno, H. Kaji, H. Ito and Y. Ikehara: A strategy for discovery of cancer glyco-biomarkers in serum using newly developed technologies for glycoproteomics, FEBS J., 277(1), 95-105 (2010).[41]A. Kuno, Y. Ikehara, Y. Tanaka, T. Angata, S. Unno, M. Sogabe, H. Ozaki, K. Ito, J. Hirabayashi, M. Mizokami and H. Narimatsu: Multilectin assay for detecting fibrosis-specific glyco-alteration by means of lectin microarray, Clin. Chem., 57(1), 48-56 (2011).[42]A. Kuno, Y. Ikehara, Y. Tanaka, K. Saito, K. Ito, C. Tsuruno, S. Nagai, Y. Takahama, M. Mizokami, J. Hirabayashi and H. Narimatsu: LecT-Hepa: a triplex lectin-antibody sandwich immunoassay for estimating the progression dynamics of liver fibrosis assisted by a bedside clinical chemistry analyzer and an automated pretreatment machine, Clin. Chim. Acta, 412(19-20), 1767-1772 (2011).[43]A. Matsuda, A. Kuno, T. Kawamoto, H. Matsuzaki, T. Irimura, Y. Ikehara, Y. Zen, Y. Nakanuma, M. Yamamoto, N. Ohkohchi, J. Shoda, J. Hirabayashi and H. Narimatsu: Wisteria floribunda agglutinin-positive mucin 1 is a sensitive biliary marker for human cholangiocarcinoma, Hepatology, 52(1), 174-182 (2010).Discussions with Reviewers1 Overall evaluationComment (Akira Ono, AIST)The author clearly describes a developmental strategy (scenario) for the research in a new scientific field as a pioneer of glycoscience. The author has appropriately selected necessary elemental technologies and successfully achieved the development. Moreover, the processes followed by the author in which the elemental technologies are integrated and applied to

※このページを正しく表示するにはFlashPlayer9以上が必要です